Shares of ProShares UltraShort Russell2000 (NYSEARCA:TWM – Free Report) are going to reverse split on Thursday, November 7th. The 1-5 reverse split was announced on Monday, October 28th. The number of shares owned by shareholders will be adjusted after the closing bell on Wednesday, November 6th.
ProShares UltraShort Russell2000 Price Performance
TWM opened at $9.26 on Tuesday. The stock has a fifty day moving average of $9.45 and a 200-day moving average of $10.38. ProShares UltraShort Russell2000 has a fifty-two week low of $8.66 and a fifty-two week high of $17.49.
Institutional Investors Weigh In On ProShares UltraShort Russell2000
An institutional investor recently raised its position in ProShares UltraShort Russell2000 stock. Hillsdale Investment Management Inc. raised its position in ProShares UltraShort Russell2000 (NYSEARCA:TWM – Free Report) by 43.4% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 60,060 shares of the company’s stock after buying an additional 18,170 shares during the quarter. Hillsdale Investment Management Inc. owned about 1.12% of ProShares UltraShort Russell2000 worth $629,000 at the end of the most recent quarter.
About ProShares UltraShort Russell2000
ProShares UltraShort Russell2000 (the Fund) seeks daily investment results that correspond to twice (200%) the inverse (opposite) of the daily performance of the Russell 2000 Index (the Index). The Fund intends to invest at least 80% of its net assets, including any borrowings for investment purposes, to investments that, in combination, have economic characteristics that are inverse to those of the Index.
Read More
- Five stocks we like better than ProShares UltraShort Russell2000
- Investing in Commodities: What Are They? How to Invest in Them
- Intel: Is Now the Time to Be Brave?Â
- What is the NASDAQ Stock Exchange?
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- What is the Dogs of the Dow Strategy? Overview and Examples
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for ProShares UltraShort Russell2000 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProShares UltraShort Russell2000 and related companies with MarketBeat.com's FREE daily email newsletter.